Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Activation in transformed cells of normal stem cells' self-renewal pathways might contribute to the survival life cycle of cancer stem cells and promote tumor progression. The BMI-1 oncogene-driven gene expression pathway is essential for the self-renewal of hematopoietic and neural stem cells. We applied a mouse/human comparative translational genomics approach to identify an 11-gene signature that consistently displays a stem cell-resembling expression profile in distant metastatic lesions as revealed by the analysis of metastases and primary tumors from a transgenic mouse model of prostate cancer and cancer patients. To further validate these results, we examined the prognostic power of the 11-gene signature in several independent therapy-outcome sets of clinical samples obtained from 1,153 cancer patients diagnosed with 11 different types of cancer, including 5 epithelial malignancies (prostate, breast, lung, ovarian, and bladder cancers) and 5 nonepithelial malignancies (lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Kaplan-Meier analysis demonstrated that a stem cell-like expression profile of the 11-gene signature in primary tumors is a consistent powerful predictor of a short interval to disease recurrence, distant metastasis, and death after therapy in cancer patients diagnosed with 11 distinct types of cancer. These data suggest the presence of a conserved BMI-1-driven pathway, which is similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as a high probability of unfavorable therapy outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated expression of this signature is associated with cancer development and chemotherapy resistance in different types of cancer, including hematological malignancies.11”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“We therefore sought to investigate whether measurements of expression of the 11-gene MTTS/PNS signature would be informative in the prediction of the patients’ prognosis in a group of 97 young women diagnosed with sporadic lymph node– negative early-stage breast cancer who were analyzed in a recent expression profilin…”
BackgroundMethodInfluentialA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Systematic determination of genetic network architecture
Tavazoie, S., Hughes, J. D., Campbell, M. J., Cho, R. J., & Church, G. M. (1999) · Nature Genetics · doi:10.1038/10343 · Cited by 2,507 · cited 1×
“We calculated the significance of the overlap between the lists of stem cell–associated and prostate cancer–associated genes by using the hypergeometric distribution test (54).”
MethodA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Cited by
Items 101–200 of 914
Balasubramanian, S., Adhikary, G., & Eckert, R. L. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp314 · Cited by 142
RetractedDeubiquitinases and the new therapeutic opportunities offered to cancer
Pfoh, R., Lacdao, I. K., & Saridakis, V. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0516 · Cited by 165
“USP22 has been identified as a cancer stem cell marker in the ‘death-from-cancer’ signature genes study (Glinsky 2005, 2006, Glinsky et al. 2005).”
BackgroundGiudice, F. S., Júnior, D. D. S. P., Nor, J. E., SQUARIZE, C. H., & CASTILHO, R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058672 · Cited by 150
Stem cells in the etiology and treatment of cancer
Zhang, M., & Rosen, J. M. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.008 · Cited by 143
Advances in the systemic therapy of malignant pleural mesothelioma
Fennell, D. A., Gaudino, G., O'Byrne, K. J., Mutti, L., & van Meerbeeck, J. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1039 · Cited by 136
“The presence of this 11-gene profile is associated with a poor prognosis in patients with MPM”
BackgroundKumar, S., Park, S. H., Cieply, B., Schupp, J., Killiam, E., Zhang, F., Rimm, D. L., & Frisch, S. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-10 · Cited by 134
“A recent large-scale gene expression profiling study indicated that the downregulation of the ank3 gene encoding ankyrin-G is one component of an 11-gene signature characteristic of chemoresistant “stem cell-like” tumors from a broad spectrum of human tumor types (34).”
BackgroundInfluentialZhao, Y., Wang, L., Ren, S., Wang, L., Blackburn, P. R., McNulty, M. S., Gao, X., Qiao, M., Vessella, R. L., Kohli, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.038 · Cited by 133
Identification of Key Processes Underlying Cancer Phenotypes Using Biologic Pathway Analysis
Efroni, S., Schaefer, C. F., & Buetow, K. H. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000425 · Cited by 132
“[22] demonstrate that gene signatures determined by small set of pre-selected canonical”
BackgroundNek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance
Marina, M. E., & Saavedra, H. I. (2014) · Frontiers in bioscience · doi:10.2741/4212 · Cited by 137
Sasaki, M., Ikeda, H., Itatsu, K., Yamaguchi, J., Sawada, S., Minato, H., Ohta, T., & Nakanuma, Y. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.52 · Cited by 140
“28 A recent report suggests the presence of a conserved Bmi-1-driven pathway to be related to a marked propensity toward metastatic disseminatio”
BackgroundHistone H2B monoubiquitination: roles to play in human malignancy
Cole, A. J., Clifton-Bligh, R. J., & Marsh, D. J. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0185 · Cited by 144
“In a seminal study carried out by Glinsky et al. (2005), USP22 was identified as part of an 11-gene signature termed the ‘death-from-cancer’ signature that predicts rapid disease recurrence, distant metastatic sites and poor response to therapy across multiple solid tumours.”
BackgroundWnt signaling and hepatocarcinogenesis: The hepatoblastoma model
Armengol, C., Cairo, S., Fabrè, M., & Buendia, M. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.07.012 · Cited by 147
Breast cancer stem cells: treatment resistance and therapeutic opportunities
Al‐Ejeh, F., Smart, C. E., Morrison, B. J., Chenevix‐Trench, G., López, J. A., Lakhani, S. R., Brown, M. P., & Khanna, K. K. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr028 · Cited by 145
Zhang, Y., Yao, L., Zhang, X., Ji, H., Wang, L., Sun, S., & Pang, D. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-0998-9 · Cited by 135
“intituled a ‘‘death from cancer signature’’ (Glinsky 2005; Glinsky et al. 2005).”
BackgroundResultInfluentialSonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells
Wang, X., Venugopal, C., Manoranjan, B., McFarlane, N., O’Farrell, E., Nolte, S., Gunnarsson, Þ., Hollenberg, R. D., Kwiecień, J. M., Northcott, P. A., et al. (2011) · Oncogene · doi:10.1038/onc.2011.232 · Cited by 143
“Bmi1 expression increases with more aggressive medulloblastoma molecular subtypes, and gene transcription profiles on CD133-sorted Daoy cells confirm cell–cell interactions within the tumor niche Bmi1 has been cited as a marker of progression in many cancer models, and it reliably predicts recurrence, poor treatment r…”
BackgroundGao, H., Yin, J., Ji, C., Yu, X., Xue, J., Guan, X., Zhang, S., Liu, X., & Xing, F. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02805-y · Cited by 144
“Structure of USP22 The open reading frame of USP22 takes charge of encoding a peptide with 525 amino acids, and its molecular weight is about 60 kDa [91].”
BackgroundEZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
Pietersen, A. M., Horlings, H. M., Hauptmann, M., Langerød, A., Ajouaou, A., Cornelissen‐Steijger, P., Wessels, L. F. A., Jonkers, J., van de Vijver, M. J., & van Lohuizen, M. (2008) · Breast Cancer Research · doi:10.1186/bcr2214 · Cited by 150
“An 11-gene signature, based on a mouse model of metastatic prostate cancer and on BMI1-deficient versus BMI1-proficient neurospheres, has been suggested to reflect BMI1-regulated 'stem cell-ness' pathways and to predict a poor outcome in breast cancer [15].”
BackgroundMethodInfluentialUsing a Stem Cell–Based Signature to Guide Therapeutic Selection in Cancer
Shats, I., Gatza, M. L., Chang, J. T., Mori, S., Wang, J., Rich, J. N., & Nevins, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1735 · Cited by 147
Andersen, M. E., M.A., H. J. C. I., Bermudez, E., Dodd, D. E., Willson, G. A., Campbell, J. L., & Thomas, R. S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq303 · Cited by 132
“Over the past 5 years, there has been increasing attention on a cancer stem cell hypothesis for tumor development (Glinsky, 2005; Glinsky et al., 2005; Lahad et al., 2005) and on the roles of Wnt/Notch, TGF-b, Hedgehog, and DNA damage control in cancer.”
BackgroundThe Lymphovascular Embolus of Inflammatory Breast Cancer Expresses a Stem Cell-Like Phenotype
Xiao, Y. Q., Ye, Y., Yearsley, K. H., Jones, S., & Barsky, S. H. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071214 · Cited by 134
Guan, Z., Wang, X.-R., Zhu, X., Huang, X.-F., Xu, J., Wang, L., Wan, X., Long, Z., Liu, J.-N., Feng, G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1379 · Cited by 128
“Recent functional microarray analysis further identified Aur-A as one of the death-from-cancer signature genes differentially regulated in tumors (18).”
BackgroundEpigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer
Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., & Johnsen, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1875 · Cited by 140
“Consistently, USP22 is upregulated in tumors with a stem cell-like phenotype from patients exhibiting overall poorer survival [106,108,109].”
BackgroundBmi-1: At the crossroads of physiological and pathological biology
Bhattacharya, R., Mustafi, S. B., Street, M., Dey, A., & Dwivedi, S. K. D. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.04.001 · Cited by 145
“Bmi-1 has been shown enriched in a population of prostate cancer cells with higher tumor initiating capacities.(115) Bmi-1 inhibition protects prostate cells from FGF10 driven hyperplasia and slows the growth of aggressive PTEN-deletion induced prostate cancer.”
BackgroundInfluentialUSP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
“Cancer Res; 74(1) January 1, 2014 Cancer Research 274”
InfluentialHasegawa, T., Yashiro, M., Nishii, T., Matsuoka, J., Fuyuhiro, Y., Morisaki, T., Fukuoka, T., Shimizu, K., Shimizu, T., Miwa, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28520 · Cited by 126
“CSCs have been proposed as having an important role in the distant metastasis of cancer cells.(4) The different interactions between CAFs and CSCs of 2 cell types might be associated with the different prognoses of the scirrhous-type and nonscirrhous-type gastric carcinomas.”
BackgroundCpG island methylation profiling in human salivary gland adenoid cystic carcinoma
Bell, A., Bell, D., Weber, R. S., & El‐Naggar, A. K. (2011) · Cancer · doi:10.1002/cncr.25818 · Cited by 135
“POU3F3 (BRN1)(16) and GBX2 are known to be involved in CNS development, with GBX2 as a direct target of the Wnt signaling pathway(17) contributing to multiple types of cancer.(18,19) TBX4 has been shown to be involved in developmental processes and breast cancer,(20) and MEIS1 homeobox gene is involved in cell differe…”
BackgroundStem Cells in Mammary Development and Carcinogenesis: Implications for Prevention and Treatment
Dontu, G., Liu, S., & Wicha, M. S. (2005) · Stem Cell Reviews and Reports · doi:10.1385/scr:1:3:207 · Cited by 126
The Leading Edge of Stem Cell Therapeutics
Singec, I., Jandial, R., Crain, A., Nikkhah, G., & Snyder, E. Y. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.070605.115252 · Cited by 126
Gennaro, V. J., Stanek, T. J., Peck, A. R., Sun, Y., Wang, F., Qie, S., Knudsen, K. E., Rui, H., Butt, T. R., Diehl, J. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807704115 · Cited by 131
“Similarly, USP22 overexpression is conserved among many aggressive forms of cancer (5, 6, 42).”
BackgroundWu, G., Qiu, X., Zhou, L., Zhu, J., Chamberlin, R., Lau, J. Y. N., Chen, P., & Lee, W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1915 · Cited by 124
“We are particularly interested in testing breast cancer, in which overexpression of Hec1 or Nek2 is linked to adverse clinical outcomes (14, 15, 25).”
Amin, M. B., Lin, D. W., Gore, J. L., Srigley, J. R., Samaratunga, H., Egevad, L., Rubin, M., Nacey, J., Carter, H. B., Klotz, L., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2014-0219-sa · Cited by 124
Concise Review: Prostate Cancer Stem Cells: Current Understanding
Skvortsov, S., Skvortsova, I., Tang, D. G., & Dubrovska, A. (2018) · Stem Cells · doi:10.1002/stem.2859 · Cited by 132
Yu, C., Lo, W., Chen, Y., Huang, P., Hsu, H., Tseng, L., Hung, S., Kao, S., Chang, C., & Chiou, S. H. (2010) · Journal of Oncology · doi:10.1155/2011/609259 · Cited by 132
“Similar results were noted in other malignancies [40].”
BackgroundResultGuo, W.-J., Zeng, M.-S., Yadav, A., Song, L.-B., Guo, B.-H., Band, V., & Dimri, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4368 · Cited by 122
“Because Bmi-1 is overexpressed in a large number of breast tumors ( 2 , 3), and because its expression inversely correlates with Mel-18 expression in breast cancer cell lines, we hypothesized that Mel-18 down-regulation may lead to Bmi-1 up-regulation in breast”
BackgroundQuantitative multi-gene expression profiling of primary prostate cancer
Schmidt, U., Fuessel, S., Koch, R., Baretton, G. B., Lohse, A., Tomasetti, S., Unversucht, S., Froehner, M., Wirth, M. P., & Meye, A. (2006) · The Prostate · doi:10.1002/pros.20490 · Cited by 122
“Furthermore, a recent report described—based on the definition of a stem cell-like gene expression profile—a ‘‘death-from-cancer’’ expression signature analyzed by microarray studies which predicted also a therapy failure for 10 different tumor entities including PCa [53].”
Dorman, S. N., Baranova, K., Knoll, J. H. M., Urquhart, B. L., Mariani, G., Carcangiu, M. L., & Rogan, P. K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.07.006 · Cited by 121
“Previous studies have derived associations between the genomic status of one ormore genes and tumor response to certain therapies (Duan et al., 2003; Glinsky et al., 2005; Hatzis et al., 2011; Ma et al., 2004; Rajput et al., 2013; van’t Veer et al., 2002).”
BackgroundGlinskii, A. B., Glinsky, G. V., Lin, H., Tang, H.-Y., Sun, M., Davis, F. B., Luidens, M. K., Mousa, S. A., Hercbergs, A. H., & Davis, P. J. (2009) · Cell Cycle · doi:10.4161/cc.8.21.9963 · Cited by 124
Self-citationPitroda, S. P., Khodarev, N. N., Beckett, M. A., Kufe, D. W., & Weichselbaum, R. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812029106 · Cited by 121
Contribution of Polycomb Homologues Bmi-1 and Mel-18 to Medulloblastoma Pathogenesis
Wiederschain, D., Chen, L., Johnson, B. V., Bettano, K. A., Jackson, D., Taraszka, J. A., Wang, Y., Jones, M. D., Morrissey, M., Deeds, J. D., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02244-06 · Cited by 136
“In addition, Bmi-1 expression has been detected at the invading front of breast tumors (25) and was found to be a strong predictor of metastasis and poor survival in a number of cancers (16).”
BackgroundThe potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities
Zaporozhchenko, I. A., Ponomaryova, A. A., RYKOVA, E. Y., & Laktionov, P. P. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1425143 · Cited by 131
Rebetz, J., Tian, D., Persson, A., Widegren, B., Salford, L. G., Englund, E. M., Gisselsson, D., & Fan, X. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001936 · Cited by 130
“pattern can serve as a marker for poor prognosis of malignant diseases [59,60].”
Yalçın, M., Dyskin, E., Lansing, L., Bharali, D. J., Mousa, S. S., Bridoux, A., Hercbergs, A. H., Lin, H., Davis, F. B., Glinsky, G. V., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1926 · Cited by 120
Self-citationEpigenetics of prostate cancer: beyond DNA methylation
Schulz, W. A., & Hatina, J. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00293.x · Cited by 116
Molecular pathways and targets in prostate cancer
Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 127
Death-From-Cancer Signatures and Stem Cell Contribution to Metastatic Cancer
Glinsky, G. V. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2001 · Cited by 116
Self-citationKhare, K., Oh, S., & Rajaratnam, B. (2014) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/rssb.12088 · Cited by 149
Nacerddine, K., Beaudry, J.-B., Ginjala, V., Westerman, B., Mattiroli, F., Song, J.-Y., van der Poel, H., Ponz, O. B., Pritchard, C., Cornelissen-Steijger, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57477 · Cited by 113
“Although previous studies suggested a positive correlation between Bmi1 expression and PCa progression (11, 13), a causal role was not demonstrated experimentally.”
Aneuploidy in health, disease, and aging
Ricke, R. M., & van Deursen, J. M. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201301061 · Cited by 112
“An alternative signature of 11 overexpressed genes associated with tumor aggressiveness and poor prognosis is enriched for mitotic factors, including CcnB1, Bub1, and Hec1/Ndc80 (Glinsky et al., 2005).”
Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling
Bilal, E., Dutkowski, J., Guinney, J., Jang, I. S., Logsdon, B. A., Pandey, G. S., Sauerwine, B., Shimoni, Y., Vollan, H. K. M., Mecham, B. H., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003047 · Cited by 124
“markers of breast cancer tumor biology that may affect clinical outcome [8–13].”
BackgroundCirculating tumor cells: detection, molecular profiling and future prospects
Jacob, K., Sollier, C., & Jabado, N. (2007) · Expert Review of Proteomics · doi:10.1586/14789450.4.6.741 · Cited by 124
Nakano, I., & Kornblum, H. I. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000203568.63482.f9 · Cited by 117
“Recently bmi-1 and its associated genes were found as critical indicators of the prognosis of various cancers including glioma, according to the cDNA microarray data set (27).”
BackgroundLee, J.-Y., Park, M. K., Park, J.-H., Lee, H. J., Shin, D. H., Kang, Y., Lee, C.-H., & Kong, G. (2013) · Oncogene · doi:10.1038/onc.2013.53 · Cited by 118
Advances in the biology of malignant pleural mesothelioma
Zucali, P. A., Ceresoli, G. L., Vincenzo, F. D., Simonelli, M., Lorenzi, E., Gianoncelli, L., & Santoro, A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.01.001 · Cited by 127
The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis
van den Hoogen, C., van der Horst, G., Cheung, H., Buijs, J. T., Pelger, R. C. M., & van der Pluijm, G. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9395-7 · Cited by 118
“It is generally believed that cellular heterogeneity in primary prostate cancers also arises from this subpopulation with stem/progenitor characteristics [4, 7, 9–11].”
BackgroundConsistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma
Mihic‐Probst, D., Kuster, A., Kilgus, S., Bode‐Lesniewska, B., Ingold‐Heppner, B., Leung, C., Storz, M., Seifert, B., Marino, S., Schraml, P., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22891 · Cited by 107
Nanta, R., Kumar, D., Meeker, D. G., Rodova, M., Veldhuizen, P. J. V., Shankar, S., & Srivastava, R. K. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.5 · Cited by 122
The Role of Genetic Markers in the Management of Prostate Cancer
Choudhury, A. D., Eeles, R. A., Freedland, S. J., Isaacs, W. B., Pomerantz, M. M., Schalken, J. A., Tammela, T. L. J., & Visakorpi, T. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.054 · Cited by 116
“Other groups have assessed the expression levels of gene sets corresponding to stem cell-like states [61,62] or markers of increased cell-cycle progression (CCP) [63], hypothesizing that these states would reflect more aggressive disease.”
BackgroundHosen, N., Yamane, T., Muijtjens, M., Pham, K., Clarke, M. F., & Weissman, I. L. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0229 · Cited by 110
Sasaki, M., Yamaguchi, J., Itatsu, K., Ikeda, H., & Nakanuma, Y. (2008) · The Journal of Pathology · doi:10.1002/path.2345 · Cited by 106
“Bmi1 is known as a potent negative regulator of the p16 INK4a gene [9,14], and Bmi1 is over-expressed in several carcinomas [14,15,17,18] and is associated with poor survival after therapy [32].”
BackgroundCharacterization of the Drugged Human Genome
Lauss, M., Kriegner, A., Vierlinger, K., & Noehammer, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1063 · Cited by 118
Ling, S., Li, J., Shan, Q., Dai, H., Lu, D., Wen, X., Song, P., Xie, H., Zhou, L., Liu, J., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12067 · Cited by 113
“Clinically, USP22 has been confirmed to predict tumor recurrence, metastasis, and poor survival after cancer diagnosis in several types of cancer (Glinsky et al., 2005; He et al., 2015).”
BackgroundThe role of Polycomb Group Proteins in Cell Cycle Regulation During Development
Martinez, A., & Cavalli, G. (2006) · Cell Cycle · doi:10.4161/cc.5.11.2781 · Cited by 122
Defining Aggressive Prostate Cancer Using a 12-Gene Model
Bismar, T. A., Demichelis, F., Riva, A., Kim, R., Varambally, S., He, L., Kutok, J. L., Aster, J. C., Tang, J., Kuefer, R., et al. (2006) · Neoplasia · doi:10.1593/neo.05664 · Cited by 107
Molecular Changes in Mesothelioma With an Impact on Prognosis and Treatment
Jean, D., Daubriac, J., Pimpec‐Barthes, F. L., Galateau-Sallé, F., & Jaurand, M. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0215-ra · Cited by 124
The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets
Allegra, A., Alonci, A., Penna, G., Innao, V., Gerace, D. G., Rotondo, F., & Musolino, C. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.958231 · Cited by 117
“greater incidence of distant metastasis than individuals with breast tumors containing a low CSC fraction (286,287).”
BackgroundAlbain, K. S., Paik, S., & Veer, L. V. (2009) · The Breast · doi:10.1016/s0960-9776(09)70290-5 · Cited by 112
M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression
Yadav, P., Subbarayalu, P., Medina, D., Nirzhor, S. S. R., Timilsina, S., Rajamanickam, S., Eedunuri, V. K., Gupta, Y. K., Zheng, S., Abdelfattah, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2106 · Cited by 111
Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer
Chou, W., Cheng, A., Brotto, M., & Chuang, C. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-300 · Cited by 108
“In agreement with previous reports [17-20], the disruption of these hub genes was observed in a variety of human tumors and often correlates with tumorigenesis.”
BackgroundResultMartínez-Ledesma, E., Verhaak, R. G. W., & Treviño, V. (2015) · Scientific Reports · doi:10.1038/srep11966 · Cited by 109
The challenges of gene expression microarrays for the study of human cancer
Tinker, A. V., Boussioutas, A., & Bowtell, D. D. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.001 · Cited by 110
“An important cancer cell May 2006 observation is that oncogene signatures can be detected within human cancers and associated with disease outcomes (Bild et al., 2005; Glinsky et al., 2004, 2005).”
BackgroundDeeb, K. K., Michalowska, A. M., Yoon, C.-Y., Krummey, S. M., Hoenerhoff, M. J., Kavanaugh, C., Li, M.-C., Demayo, F. J., Linnoila, I., Deng, C.-X., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1515 · Cited by 102
“Previous studies have also used mouse models to identify important gene signatures related to particular oncogenic pathways relevant to human cancers, including prostate (37, 38), liver (39), lung (40), and breast (41).”
BackgroundLiu, Y., Yang, Y., Xu, H., & Dong, X. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21802 · Cited by 101
“Recent experimental observations have identified a conserved BMI1-driven 11-gene signature as a key regulator of ‘‘stemness’’ in both tissue stem cells and cancer stem cells; cancer stem cells are considered essential for tumor progression and metastases of epithelial malignancies [4,5].”
BackgroundResultInfluentialThe EMT signaling pathways in endometrial carcinoma
Colás, E., Pedrola, N., Devis, L., Ertekin, T., Campoy, I., Martínez-García, E., Llauradó, M., Rigau, M., Oliván, M., García, M., et al. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0866-3 · Cited by 112
DUBs, the regulation of cell identity and disease
Heideker, J., & Wertz, I. E. (2015) · Biochemical Journal · doi:10.1042/bj20140496 · Cited by 98
BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases
Hoenerhoff, M. J., Chu, I., Barkan, D., Liu, Z.-Y., Datta, S., Dimri, G. P., & Green, J. E. (2009) · Oncogene · doi:10.1038/onc.2009.165 · Cited by 101
“Additionally, BMI1 has recently been associated with a stem cell-like 11 gene expression microarray signature predictive of a short interval to disease recurrence following therapy, increased likelihood of metastatic disease, and poor response to therapy in multiple types of human cancer, including prostate, lung, ova…”
BackgroundInfluentialTanaka, S., Arii, S., Yasen, M., Mogushi, K., Su, N., Zhao, C. N., Imoto, I., Eishi, Y., Inazawa, J., Miki, Y., et al. (2008) · British journal of surgery · doi:10.1002/bjs.6011 · Cited by 105
Ubiquitin-specific peptidase 22 functions and its involvement in disease
Melo‐Cardenas, J., Zhang, Y., Zhang, D. D., & Fang, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8602 · Cited by 103
“Some of the genes in this signature profile have been previously involved with processes such as mitosis and chromatin remodeling [54].”
BackgroundTranscriptional landscape of human cancers
Li, M., Sun, Q., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15837 · Cited by 101
Guo, W., Lasky, J. L., & Wu, H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000203592.04530.06 · Cited by 120
“molecular signature of 11 genes in metastatic cancer (44).”
BackgroundAnzengruber, F., Avci, P., de Freitas, L. F., & Hamblin, M. R. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00455h · Cited by 103
Datta, S., Hoenerhoff, M. J., Bommi, P., Sainger, R., Guo, W.-J., Dimri, M., Band, H., Band, V., Green, J. E., & Dimri, G. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1636 · Cited by 97
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects
Wouters, B. J., Löwenberg, B., & Delwel, R. (2008) · Blood · doi:10.1182/blood-2008-04-153239 · Cited by 105
Calés, C., Román-Trufero, M., Pavón, L., Serrano, I., Melgar, T., Endoh, M., Pérez, C., Koseki, H., & Vidal, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01136-07 · Cited by 95
“Similarly, Ring1B protein expression is increased in a variety of tumors (60), and its expression correlates with poor prognosis in a subset of malignant human cancers (24).”
BackgroundLi, J., Gong, L.-Y., Song, L.-B., Jiang, L.-L., Liu, L.-P., Wu, J., Yuan, J., Cai, J.-C., He, M., Wang, L., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090502 · Cited by 84
An Atlas of Altered Expression of Deubiquitinating Enzymes in Human Cancer
Luise, C., Capra, M. C., Donzelli, M., Mazzarol, G., Jodice, M. G., Nuciforo, P. G., Viale, G., Fiore, P. P. D., & Confalonieri, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015891 · Cited by 97
“Another example is represented by USP22, which is part of a small set of marker genes capable of predicting metastatic potential and therapeutic outcome in human cancer [39,40].”
BackgroundPopay, T. M., Wang, J., Adams, C. M., Howard, G. C., Codreanu, S. G., Sherrod, S. D., MCLEAN, J. A. J., Thomas, L. R., Lorey, S. L., Machida, Y., et al. (2021) · eLife · doi:10.7554/elife.60191 · Cited by 99
“We also note that HCF-1 has been reported to be overexpressed in cancer, and its overexpression can correlate with poor clinical outcomes (Glinsky et al., 2005).”
BackgroundKikuchi, J., Kinoshita, I., Shimizu, Y., Kikuchi, E., Konishi, J. S., Oizumi, S., Kaga, K., Matsuno, Y., Nishimura, M., & Dosaka‐Akita, H. (2010) · Cancer · doi:10.1002/cncr.25128 · Cited by 94
“The inverse correlation between Bmi1 expression and pT classification was unexpected because of its oncogenic potential, including its negative regulation of the Ink4a/Arf locus(9,10) and its role in stem cell maintenance.(11,12) In previous NSCLC studies, Vonlanthen et al(18) reported no association of Bmi1 expressio…”
BackgroundBmi‐1 is related to proliferation, survival and poor prognosis in pancreatic cancer
Song, W., Tao, K., Li, H., Chen, J., Song, Z., Li, J., Shi, H. Y., Li, X., Dang, Z., & Dou, K. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01577.x · Cited by 92
Tomao, F., Papa, A., Rossi, L., Strudel, M., Vici, P., Lo Russo, G., & Tomao, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-48 · Cited by 92
“cells as well [104-110].”
Mimeault, M., & Batra, S. K. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0785 · Cited by 91
“loid leukemia, lymphoma, mesothelioma, medulloblastoma, glioma, and prostate, breast, lung, ovarian, and bladder epithelial cancers (4).”
InfluentialPrognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study
Vrzalikova, K., Škarda, J., Ehrmann, J., Murray, P. G., Fridman, E., Kopolovic, J., Hamerlik, P., Hajdúch, M., Klein, J., Kolek, V., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0361-y · Cited by 98
“Recent data suggest the presence of a conserved Bmi-1-driven pathway which is, analogously to stem cells, also involved in the development of a highly malignant subset of human cancers ( Glinsky et al. 2005 ).”
BackgroundUbiquitin-specific protease 22 is a deubiquitinase of CCNB1
Lin, Z., Tan, C., Qiu, Q., Kong, S., Yang, H., Zhao, F., Liu, Z., Li, J., Kong, Q., Gao, B., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.28 · Cited by 90
“USP22 has also been identified as a death-from-cancer signature gene [2, 3].”
The enigmatic role of H2Bub1 in cancer
Johnsen, S. A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.002 · Cited by 97
“USP22 Removal of H2Bub1 Associated with stem cell phenotype and poor prognosis [54]”
BackgroundInfluentialNalwoga, H., Arnes, J. B., Wabinga, H., & Akslen, L. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605488 · Cited by 89
“This definition for luminal B tumours does not identify all luminal B tumours because only 30– 50% are HER2þ and the rest are classified with the luminal A.”
BackgroundGuo, S., Xu, X., Tang, Y., Zhang, C., Li, J., Ouyang, Y., Ju, J., Bie, P., & Wang, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.009 · Cited by 93
Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer
Jeusset, L. M., & McManus, K. J. (2019) · Cells · doi:10.3390/cells8020165 · Cited by 97
“USP22 overexpression is part of the “death from cancer” signature [113] and observed in multiple cancer types, including breast cancer and colorectal cancer [89,114–119] Preclinical study indicates that RNF20-depleted cells can be selectively targeted with PARP1 inhibitor via a synthetic lethal strategy [120]”
BackgroundHuman endogenous retroviruses role in cancer cell stemness
Matteucci, C., Balestrieri, E., Argaw-Denboba, A., & Vallebona, P. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.10.001 · Cited by 98
Brunner, M., Thurnher, D., Pammer, J., Geleff, S., Heiduschka, G., Reinisch, C. M., Petzelbauer, P., & Erović, B. M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.63 · Cited by 103
Wei, R. L.-H., Ngo, B., Wu, G., & Lee, W. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-01-0012 · Cited by 97
“primary breast cancers and cases with multiple cancers (Chen et al., 1997; van’t Veer et al., 2002; Glinsky et al., 2005).”
Zhu, S. L., Zhao, D., Lin, Y., Jiang, W., Kim, J., Gu, B., Liu, Q., Wang, R., Xia, B., Zhao, J. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02863-3 · Cited by 90
Metadata
- Authors
- Glinsky, G. V., Berezovska, O., & Glinskii, A. B.
- Affiliations
- Sidney Kimmel Cancer Center (US)
- Corresponding author
- Glinsky, Gennadi V.
- ORCID
- Glinsky, Gennadi V.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1503-1521
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1136989
- OpenAlex
- W2166666333
- Cited by
- 916
- References
- 68
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 22 · 2023: 30 · 2022: 25 · 2021: 29 · 2020: 25 · 2019: 27 · 2018: 38 · 2017: 35 · 2016: 30 · 2015: 50 · 2014: 57 · 2013: 51 · 2012: 60
- FWCI
- 34.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (5R01CA89827, R01CA089827)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- cancer stem cells, BMI1, stem cell self-renewal, gene expression signatures, metastasis, treatment failure, prognosis, distant metastasis, recurrence, epithelial malignancies, hematologic malignancies, multi-cancer analysis
- MeSH terms
- Animals, Female, Humans, Male, Mice, Transgenic, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Nuclear Proteins, Prognosis, Proto-Oncogene Proteins, Repressor Proteins, Biomarkers, Tumor, Neoplastic Stem Cells, Gene Expression Regulation, Neoplastic, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Polycomb Repressive Complex 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.